Cost cut for cancer drug

MORE than 3000 breast cancer patients will get access to cheaper medication after the cost of a life-changing drug was slashed.

The Federal Government yesterday listed ribociclib, which has the brand name Kisqali, on the Pharmaceutical Benefits Scheme.

This medication would otherwise cost patients more than $70,000 a year but under the PBS patients will pay $39.50 a script and $6.40 for concession holders.

The drug slows the progression of breast cancer.